Search
MenABCWY QUINTET Study Meningococcal disease is a rare but serious disease that can result in death if not recognised and treated quickly. There are
News & Events
Major funding aims to improve skin cancer outcomes for young Aboriginal peopleVital research promoting sun smart choices and skin cancer prevention for young Aboriginal people is now underway at The Kids Research Institute Australia thanks to a $100,000 Perpetual 2024 IMPACT Philanthropy grant.
PICOBOO (The Platform Trial In COVID-19 Priming and BOOsting) Study and NOVAVAX COVID-19/Influenza Combined Vaccine Study
Research
Optimising a 6-plex tetanus-diphtheria-pertussis fluorescent bead-based immunoassaySmall volume assays are required for large-scale research studies and in particular paediatric trials, where multiple measures are required from a single sample. Fluorescent bead-based technology (Bioplex/Luminex) allows high through-put and simultaneous quantification of multiple analytes in a single test. This technology uses sets of microspheres, each with a unique spectral address that can be coated with a different antigen of interest.
News & Events
Six-minute Strep A tests dramatically cut wait time in remote settingsChildren at risk of potentially life-threatening Strep A infections no longer have to wait five days for timely treatment, thanks to a The Kids Research Institute Australia study conducted in the remote Kimberley region of Western Australia.
Find out more about the scholarship opportunities at the Wesfarmers Centre, including Training Scholarships and Higher Degree by Research Scholarships.
News & Events
Whooping cough vaccine could be a new weapon in the fight against food allergiesResearchers from The Kids Research Institute Australia and Curtin University will use a $3.9 million grant from the National Health and Medical Research Council to investigate whether a type of whooping cough vaccine could provide bonus protection against food allergies and eczema.
Research
A blueprint for a multi-disease, multi-domain Bayesian adaptive platform trial incorporating adult and paediatric subgroups: the Staphylococcus aureus Network Adaptive Platform trialThe Staphylococcus aureus Network Adaptive Platform (SNAP) trial is a multifactorial Bayesian adaptive platform trial that aims to improve the way that S. aureus bloodstream infection, a globally common and severe infectious disease, is treated. In a world first, the SNAP trial will simultaneously investigate the effects of multiple intervention modalities within multiple groups of participants with different forms of S. aureus bloodstream infection.
Research
Respiratory Syncytial Virus Reinfections in Children in Western AustraliaRespiratory syncytial virus (RSV) reinfection in children is poorly understood. We examined the incidence, characteristics, and outcomes of hospital-attended RSV reinfections in children <16 years in Western Australia between 2012 and 2022.
Research
Walking the walk to include pregnant participants in non-obstetric clinical trials: Insights from the SNAP TrialDespite several calls for greater inclusion of pregnant people in non-obstetric clinical trials, their systematic exclusion remains common practice. Excluding pregnant individuals from clinical trials may result in unintended consequences such as inadequate treatment of medical conditions in pregnancy, inappropriate dosing of medications, and investigational therapies being used off-label outside of the context of a clinical trial, risking adverse events in the absence of demonstrated efficacy.